| 472-1 |
sulfiSOXAZOLE |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
sulfiSOXAZOLE [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
472-1 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Sulfisoxaz Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Gantrisin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sulfizole; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4720-9 |
HLA-A23(9) |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A23(9) [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4720-9 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A23(9) Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47200-1 |
Methionine+Homocysteine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Methionine+Homocysteine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
47200-1 |
|
|
|
|
Observation |
|
|
|
0 |
Methionine+Homocysteine Dose |
|
|
|
N |
|
Dose med or substance; DRUG DOSES; HCY; Hcys; Hcyst; Homocyst(e)ine; Met; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
2.19 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 47201-9 |
Bentiromide |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Bentiromide [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
47201-9 |
|
|
|
|
Observation |
|
|
|
0 |
Bentiromide Dose |
|
|
|
N |
|
Bentiramide; Dose med or substance; DRUG DOSES; N-benzoyl-L-tyrosylp-aminobenzoic acid; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
2.19 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 47202-7 |
Sincalide |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Sincalide [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
47202-7 |
|
|
|
|
Observation |
|
|
|
0 |
Sincalide Dose |
|
|
|
N |
|
Dose med or substance; DRUG DOSES; Kinevac; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
2.19 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 47203-5 |
Pyridoxine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Pyridoxine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
47203-5 |
|
|
|
|
Observation |
|
|
|
0 |
Vit B6 Dose |
|
|
|
N |
|
C8H11NO3; Dose med or substance; DRUG DOSES; Point in time; Pyridoxol; QNT; Quan; Quant; Quantitative; Random; Vit B6; Vitamin B6 |
2.69 |
2.19 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 47204-3 |
glipiZIDE |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
glipiZIDE [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
47204-3 |
|
|
|
|
Both |
|
|
|
0 |
glipiZIDE Ur Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Glucotrol; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47205-0 |
metyraPONE |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
metyraPONE [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
g |
|
|
|
|
|
|
DRUGDOSE |
|
47205-0 |
|
|
|
|
Observation |
|
|
|
0 |
metyraPONE Dose |
|
|
|
N |
|
Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.19 |
|
|
|
|
|
|
|
g |
|
|
|
0 |
| 47206-8 |
Corticotropin |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
ug |
|
|
|
|
|
|
DRUGDOSE |
|
47206-8 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH Dose |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; c206; c74; Cortrosyn; Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Tumor marker |
2.7 |
2.19 |
|
|
|
|
|
|
|
ug |
|
|
|
0 |
| 47207-6 |
Secretin |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Secretin [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
47207-6 |
|
|
|
|
Observation |
|
|
|
0 |
Secretin Dose |
|
|
|
N |
|
Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
2.19 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 47208-4 |
Arginine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Arginine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
47208-4 |
|
|
|
|
Observation |
|
|
|
0 |
Arginine Dose |
|
|
|
N |
|
Arg; Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
2.19 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 47209-2 |
Glucagon |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Glucagon [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
47209-2 |
|
|
|
|
Observation |
|
|
|
0 |
Glucagon Dose |
|
|
|
N |
|
Dose med or substance; DRUG DOSES; HGF; Hyperglycemic factor; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.19 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4721-7 |
HLA-A24(9) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A24(9) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4721-7 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A24(9) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47210-0 |
Triglyceride^post CFst |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Triglyceride [Moles/volume] in Serum or Plasma --fasting |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
47210-0 |
|
|
|
|
Both |
|
|
|
0 |
Trigl p fast SerPl-sCnc |
|
|
|
N |
|
After; Calorie Fast; Cardio; Cardiology; Chemistry; Fast; Fasting; Heart Disease; Level; p fast; PC; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tg; Trig; Trigly; Triglycerides; Triglycrides |
2.7 |
2.19 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 47211-8 |
Chlamydia trachomatis L2 DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Chlamydia trachomatis L2 DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Positive for Chlamydia trachomatis serovar L2 DNA by real-time PCR |
|
|
|
|
|
MICRO |
|
47211-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C trach L2 DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C trac; C trach; C trach L2; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; LGV; Ligase chain reaction; Ligation-activated transcription; Lymphogranuloma venereum; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Trachoma; Transcription mediated amplification; Unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47212-6 |
Chlamydia trachomatis DNA |
Prid |
XXX |
Pt |
Nom |
Probe.amp.tar |
|
ACTIVE |
Chlamydia trachomatis DNA [Identifier] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
DNA sequencing has determined the serovar as Chlamydia trachomatis serovar B |
|
|
|
|
|
MICRO |
|
47212-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C trach DNA Spec NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Identity or presence; Infectious Disease; InfectiousDisease; LAT; LCR; LGV; Ligase chain reaction; Ligation-activated transcription; Lymphogranuloma venereum; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Trachoma; Transcription mediated amplification; Unspecified |
2.69 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 47213-4 |
Cholesterol.in LDL real size pattern |
Prid |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Cholesterol in LDL real size pattern [Identifier] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
47213-4 |
|
|
|
|
Observation |
|
|
|
0 |
LDLc real size Pat SerPl |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; Identity or presence; LDLc; LDL-C; LDLc real size Pat; Lipid; Low density lipoprotein cholesterol; Low density lipoprotein cholesterols; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 47214-2 |
Homeostasis model assessment |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Homeostasis model assessment |
|
MIN |
DefinitionDescription |
|
|
Index |
|
|
|
|
|
|
CHEM |
|
47214-2 |
|
|
|
|
Both |
|
|
|
0 |
HOMA SerPl-aCnc |
|
|
|
N |
|
Arbitrary concentration; Chemistry; HOMA; Homeostatis Model Assessment; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
{Index_val} |
|
|
|
0 |
| 47215-9 |
Lipoprotein.beta.subparticle.medium |
EntLen |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Lipoprotein.beta.subparticle.medium [Entitic length] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nm |
|
|
|
|
|
|
CHEM |
|
47215-9 |
|
|
|
|
Observation |
|
|
|
0 |
LDL med SerPl Qn |
|
|
|
N |
|
B; Chemistry; Entitic length; LDL; LDL med; Lip; Lipoprot; Lipoproteins; Low density lipoproteins; LP; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
nm |
|
|
Release 2.69: COMPONENT: Update "intermediate" to "medium" to align with current nomenclature; |
0 |
| 47216-7 |
Hepatitis B virus DNA |
NCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar detection limit = 200 copies/mL |
|
ACTIVE |
Hepatitis B virus DNA [#/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 200 copies/ml |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
47216-7 |
|
Probe.amp.tar detection limit = 200 copies/mL |
|
|
Both |
|
|
|
0 |
HBV DNA # SerPl NAA DL=200 |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HBV; Hep; Hep B; Hepatis; Hepatit; Hepatology; HepB; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Liver; Microbiology; NAA DL=200; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.19 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 47217-5 |
Immune complex.C3d |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Immune Complex C3d [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
SERO |
|
47217-5 |
|
|
|
|
Both |
|
|
|
0 |
IC C3d SerPl-mCnc |
|
|
|
N |
|
CIC; Circulating immune complex; Compx; IC; IC C3d; Imm; Imun; Imune; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 47218-3 |
Cholesterol.in VLDL 3+4 |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in VLDL 3+4 [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
47218-3 |
|
|
|
|
Observation |
|
|
|
0 |
VLDL3+4c SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; III; Level; Lipid; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Very low density lipoprotein cholesterols; VLDL3+4c; VLDL3c; VLDLc |
2.34 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 47219-1 |
Cholesterol.in VLDL 5+6 |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in VLDL 5+6 [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
47219-1 |
|
|
|
|
Observation |
|
|
|
0 |
VLDL5+6c SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; Level; Lipid; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Very low density lipoprotein cholesterols; VLDL5+6c; VLDLc |
2.34 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 4722-5 |
HLA-A25(10) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A25(10) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4722-5 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A25(10) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47220-9 |
Cholesterol.in HDL 4+5 |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in HDL 4+5 [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
47220-9 |
|
|
|
|
Observation |
|
|
|
0 |
HDL4+5c SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; HDL4+5c; HDLc; HDL-C; Heart Disease; High density lipoprotein cholesterols; Level; Lipid; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TCHHDL |
2.34 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
